A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Trastuzumab is a standard treatment for HER2-positive (HER2(+)) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2(+) metastatic breast cancer (MBC)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Li, Huiping, Liu, Jiang, Chen, Jianing, Wang, Huiyun, Yang, Linbin, Chen, Fei, Fan, Siting, Wang, Jing, Shao, Bin, Yin, Dong, Zeng, Musheng, Li, Mengfeng, Li, Jun, Su, Fengxi, Liu, Qiang, Yao, Herui, Su, Shicheng, Song, Erwei
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915573/
https://ncbi.nlm.nih.gov/pubmed/29691399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03537-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados